Will Novo Nordisk report Q2 2026 results with obesity guidance by 15 October 2026?
Posted 2026-08-24 — 75 days before the deadline, stated before the outcome.
Novo Nordisk is a Danish pharmaceutical company known for developing treatments for diabetes and obesity. The company regularly publishes quarterly financial reports that include performance metrics and strategic guidance for its product lines.
The claim
Novo Nordisk will report full Q2 2026 financial results, including specific guidance updates for its obesity portfolio, by 15 October 2026.
Reasoning trace
- Upstream shock: Eli Lilly (z=4.6); Novo Nordisk exposed via 'uses' edge
Evidence so far
2 confirming · 0 denying signals · 11 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 22 times since mint (last on 2026-10-11) — 93% at mint → 74% today.
What to watch
- milestone Novo Nordisk files its Q2 2026 Form 20-F or equivalent quarterly regulatory filing with the Danish Financial Supervisory Authority (FSA) or US SEC observed
- leading indicator Novo Nordisk announces the scheduled date for its Q2 2026 earnings release via a press release or exchange notification observed
- milestone Novo Nordisk files its Q2 2026 quarterly report (Form 20-F or equivalent local filing) with the Danish Financial Supervisory Authority (FSA) or SEC observed
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.